Ocugen, Inc. (OCGN) Latest Company News

Sep 1, 2026, 11:02 UTC
Ocugen dosed the first patient in the global Phase 3 registrational trial of its OCU410 modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration.
Source:
- globenewswire.com
- zacks.com
Aug 16, 2026, 01:03 UTC
Ocugen announced plans to file Biologics License Applications (BLAs) for its gene therapy programs targeting inherited retinal diseases and dry age-related macular degeneration, with filings expected in 2027.
Source:
- marketbeat.com
Aug 6, 2026, 14:51 UTC
Ocugen reported a quarterly loss of $0.07 per share for Q2 2026, missing the Zacks Consensus Estimate of a loss of $0.05.
Source:
Aug 6, 2026, 11:02 UTC
Ocugen received FDA clearance to initiate a Phase 3 trial for OCU410 in geographic atrophy and was granted RMAT designation for OCU410.
Source:
- globenewswire.com
- marketbeat.com
Aug 6, 2026, 11:02 UTC
Ocugen closed a $130.0 million convertible senior notes financing, extending cash runway into 2028.
Source:
- globenewswire.com
Aug 6, 2026, 11:02 UTC
Ocugen strengthened its leadership team with the appointment of Mohamed Genead, M.D.
Source:
- globenewswire.com
Aug 6, 2026, 00:00 UTC
Ocugen, Inc. used $32.7 million of the convertible notes proceeds to retire a loan from Avenue Capital.
Jul 29, 2026, 11:01 UTC
Ocugen announced that the U.S. Food and Drug Administration granted RMAT designation to its investigational product OCU410 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
Source:
- globenewswire.com
Jul 13, 2026, 11:02 UTC
Ocugen signed a binding term sheet with Roots Pharmaceutical to license OCU400 gene therapy for retinitis pigmentosa in the Middle East and North Africa region.
Source:
- globenewswire.com
- globenewswire.com
Jun 3, 2026, 00:00 UTC
Ramesh Ramachandran resigned as Chief Accounting Officer of Ocugen, Inc., effective May 29, 2026, and Rita Johnson-Greene was appointed as principal accounting officer, effective June 3, 2026.
May 7, 2026, 00:00 UTC
Ocugen, Inc. signed a private offering of $115.0 million aggregate principal amount of 6.75% convertible senior notes due 2034, convertible into Ocugen common stock, with net proceeds of approximately $99.5 million, of which about $32.7 million will be used to repay an existing loan.

OCGN

Ocugen dosed the first patient in the global Phase 3 registrational trial of its OCU410 modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration.

Ocugen announced plans to file Biologics License Applications (BLAs) for its gene therapy programs targeting inherited retinal diseases and dry age-related macular degeneration, with filings expected in 2027.

Ocugen reported a quarterly loss of $0.07 per share for Q2 2026, missing the Zacks Consensus Estimate of a loss of $0.05.

Ocugen received FDA clearance to initiate a Phase 3 trial for OCU410 in geographic atrophy and was granted RMAT designation for OCU410.

Ocugen closed a $130.0 million convertible senior notes financing, extending cash runway into 2028.

Ocugen strengthened its leadership team with the appointment of Mohamed Genead, M.D.

Ocugen, Inc. used $32.7 million of the convertible notes proceeds to retire a loan from Avenue Capital.

Ocugen announced that the U.S. Food and Drug Administration granted RMAT designation to its investigational product OCU410 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.

Ocugen signed a binding term sheet with Roots Pharmaceutical to license OCU400 gene therapy for retinitis pigmentosa in the Middle East and North Africa region.

Ramesh Ramachandran resigned as Chief Accounting Officer of Ocugen, Inc., effective May 29, 2026, and Rita Johnson-Greene was appointed as principal accounting officer, effective June 3, 2026.

Ocugen, Inc. signed a private offering of $115.0 million aggregate principal amount of 6.75% convertible senior notes due 2034, convertible into Ocugen common stock, with net proceeds of approximately $99.5 million, of which about $32.7 million will be used to repay an existing loan.